Last reviewed · How we verify
NCT04663412
Indocyanine Green Fluorescence Imaging, Sentinel Lymph Node Mapping in Patients With Vulvar Cancer
NA trial testing Sentinel lymph node mapping with indocyanine green fluorescence imaging in vulvar cancer (FIGO Stage IB) in Vulvar Cancer in 2 participants. Status unknown.
20 July 2021
Quick facts
| Lead sponsor | Azienda Ospedaliera per l'Emergenza Canizzaro |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 2 |
| Start date | 9 July 2020 |
| Primary completion | 20 July 2021 |
| Estimated completion | 20 July 2023 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Sentinel lymph node mapping with indocyanine green fluorescence imaging in vulvar cancer (FIGO Stage IB)
Conditions studied
- Vulvar Cancer — all drugs for Vulvar Cancer →
Sponsor
Azienda Ospedaliera per l'Emergenza Canizzaro
Who can join
Adults 20 to 100, female only, with Vulvar Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The potential of the administration of indocyanine green (ICG) allows the execution of SLN biopsy, avoiding the multiple administrations of radiocolloid in the pre-operative phase, painful for the patient, elimination, and exposure to radioactivity. Therefore, while requiring standardization of the methodology and a large-scale application, this procedure could open a new surgical management perspective in patients with early-stage vulvar cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04663412
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Vulvar Cancer
Currently open trials in the same condition.
- NCT07124000 — DESTINY-PANTUMOUR04 · recruiting
- NCT05639972 — E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers · Phase 1, PHASE2 · recruiting
- NCT06677190 — Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin · Phase 2 · recruiting
- NCT05576831 — STRatIfication of Vulvar Squamous Cell Carcinoma by HPV and p53 Status to Guide Excision · NA · recruiting
- NCT06495554 — Danish Vulva Cancer Recurrence Study · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04663412 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Azienda Ospedaliera per l'Emergenza Canizzaro
- Last refreshed: 11 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04663412.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing